Tuesday 29th June 2021, 16.30 - 17.30
Join this webinar to hear Dr Charlotte Milner-Watts update on the use of Durvalumab in the treatment of unresectable stage III NSCLC. Covering specifically
- Therapeutic indication, rationale, schedule
- PACIFIC – key trial data
- Toxicity management
- Follow up
- Case studies
Our webinars are for healthcare professionals only.
Watch On Demand
Speakers
Dr Charlotte Milner-Watts
I am a clinical fellow in the lung unit at the Royal Marsden Hospital. I treat patients with lung cancer, mesothelioma and thymic carcinoma, in the standard of care, clinical trial and compassionate/expanded access settings. I have experience in the use of chemotherapy, immunotherapy and targeted therapy. I recruit patients to clinical trials and manage their care as they proceed on study. I actively participate in research meetings and the MDT. I have a particular interest in molecular-driven lung cancer and participate in the presentation and review of molecular results at our Genomics Tumour Advisory Board.
Paula Shepherd
LCNUK Committee member. Paula Shepherd currently works as a Lung Cancer CNS at Liverpool University Hospital Foundation Trust . She qualified as an RGN in 2001 and her main experience has been gained within respiratory medicine, with a particular interest being lung cancer. She has been a Respiratory CNS since 2009 and began her role as a Lung Cancer CNS in 2011, moving to her current Trust in 2013. Paula has completed numerous role specific degree modules previously and became a Non-Medical prescriber in March 2017. She is currently undertaking a MSc in advanced clinic practice, with her completed modules including, context of advanced practice, acute oncology, cardiorespiratory/neurology clinical examination and diagnostics, leadership, research and interpretation of medical imaging. Her role as a Lung Cancer CNS involves supporting patients throughout their pathway from pre-diagnosis through to palliative care. Paula has previously presented at the LCNUK conferences and was delighted to become a member of the committee in 2020.
